The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Monique W. J. den Brok

Slotervaart Hospital/The Netherlands Cancer Institute

Department of Pharmacy & Pharmacology

1066 EC Amsterdam

[email]@slz.nl

Name/email consistency: low

 
 
 
 
 
 
 

Affiliations

  • Slotervaart Hospital/The Netherlands Cancer Institute, Department of Pharmacy & Pharmacology, 1066 EC Amsterdam. 2004 - 2006
  • Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Slotervaart Hospital, Louwesweg 6, Netherlands. 2003 - 2005

References

  1. Compatibility and stability of the novel anticancer agent ES-285 x HCl formulated with 2-hydroxypropyl-beta-cyclodextrin in infusion devices. Den Brok, M.W., Nuijen, B., García, J.L., Miranda, E., Calvo, P., Manada, C., Beijnen, J.H. Pharmazie (2006) [Pubmed]
  2. Pharmaceutical development of a lyophilised dosage form for the investigational anticancer agent Imexon using dimethyl sulfoxide as solubilising and stabilising agent. den Brok, M.W., Nuijen, B., Lutz, C., Opitz, H.G., Beijnen, J.H. J. Pharm. Sci (2005) [Pubmed]
  3. Development and validation of an LC-UV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form. den Brok, M.W., Nuijen, B., Hillebrand, M.J., Grieshaber, C.K., Harvey, M.D., Beijnen, J.H. J. Pharm. Biomed. Anal (2005) [Pubmed]
  4. LC-UV method development and validation for the investigational anticancer agent imexon and identification of its degradation products. den Brok, M.W., Nuijen, B., Hillebrand, M.J., Lutz, C., Opitz, H.G., Beijnen, J.H. J. Pharm. Biomed. Anal (2005) [Pubmed]
  5. Compatibility and stability of Imexon in infusion devices and its in vitro biocompatibility. den Brok, M.W., Nuijen, B., Challa, E.E., Lutz, C., Opitz, H.G., Beijnen, J.H. Anticancer. Drugs (2005) [Pubmed]
  6. Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl. Den Brok, M.W., Nuijen, B., Meijer, D.M., Millán, E., Manada, C., Beijnen, J.H. PDA. J. Pharm. Sci. Technol (2005) [Pubmed]
  7. Pharmaceutical development of a parenteral lyophilised dosage form for the novel anticancer agent C1311. Den Brok, M.W., Nuijen, B., Kettenes-Van Den Bosch, J.J., Van Steenbergen, M.J., Buluran, J.N., Harvey, M.D., Grieshaber, C.K., Beijnen, J.H. PDA. J. Pharm. Sci. Technol (2005) [Pubmed]
  8. Compatibility and stability of the novel anti-cancer agent C1311 in infusion devices and its in vitro biocompatibility. den Brok, M.W., Nuijen, B., Harms, R., Buluran, J.N., Harvey, M.D., Grieshaber, C.K., Beijnen, J.H. J. Oncol. Pharm. Pract (2005) [Pubmed]
  9. 2-Hydroxypropyl-beta-cyclodextrin extracts 2-phenylphenol from silicone tubing. den Brok, M.W., van der Schoot, S.C., Nuijen, B., Hillebrand, M.J., Beijnen, J.H. Int. J. Pharm (2004) [Pubmed]
  10. Development and validation of a liquid chromatography-ultraviolet absorbance detection assay using derivatisation for the novel marine anticancer agent ES-285 x HCl [(2S,3R)-2-amino-3-octadecanol hydrochloride] and its pharmaceutical dosage form. den Brok, M.W., Nuijen, B., Miranda, E., Floriano, P., Munt, S., Manzanares, I., Beijnen, J.H. J. Chromatogr. A (2003) [Pubmed]
 
WikiGenes - Universities